Results 1 to 10 of about 98,172 (269)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells [PDF]

Scientific Reports, 2022
In this study, we examined the antileukemic effects of pterostilbene, a natural methylated polyphenol analog of resveratrol that is predominantly found in berries and nuts, using various human and murine leukemic cells, as well as bone marrow samples ...
Shohei Kawakami, Mitsuyo Tsuma-Kaneko, Masakazu Sawanobori, Tomoko Uno, Yoshihiko Nakamura, Hideyuki Matsuzawa, Rikio Suzuki, Makoto Onizuka, Takashi Yahata, Kazuhito Naka, Kiyoshi Ando, Hiroshi Kawada   +11 more
doaj   +5 more sources

I13 overrides resistance mediated by the T315I mutation in chronic myeloid leukemia by direct BCR-ABL inhibition [PDF]

Frontiers in Pharmacology, 2023
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a BCR-ABL fusion gene. Imatinib has significantly improved the treatment of CML as a first-generation tyrosine kinase inhibitor (TKIs). The T315I mutant form of BCR-ABL is the most
Congying Gao, Lei Zhang, Yun Xu, Xiangyu Ma, Peilei Chen, Zhe-Sheng Chen, Liuya Wei   +6 more
doaj   +2 more sources

Cardiac arrhythmias of BCR-ABL inhibitors with or without triazole antifungal agents: A real-world pharmacovigilance study based on the food and drug administration adverse event reporting system database [PDF]

SAGE Open Medicine
Objectives: Breakpoint Cluster Region (BCR)-Abelson tyrosine kinase (ABL) inhibitors are widely used in the treatment of blood cancers, particularly chronic myelogenous leukemia and are often combined with triazole antifungal agents to prevent fungal ...
Peitao Xie, Lishan Lu, Yixuan Tian, Rongrong Jia, Xuemei Tian, Pu Bai   +5 more
doaj   +2 more sources

New Inhibitors of Bcr-Abl Based on 2,6,9-Trisubstituted Purine Scaffold Elicit Cytotoxicity in Chronic Myeloid Leukemia-Derived Cell Lines Sensitive and Resistant to TKIs [PDF]

Pharmaceutics
Bcr-Abl is an oncoprotein with aberrant tyrosine kinase activity involved in the progression of chronic myeloid leukemia (CML) and has been targeted by inhibitors such as imatinib and nilotinib.
Thalia Delgado, Denisa Veselá, Hana Dostálová, Vladimír Kryštof, Veronika Vojáčková, Radek Jorda, Alejandro Castro, Jeanluc Bertrand, Gildardo Rivera, Mario Faúndez, Miroslav Strnad, Christian Espinosa-Bustos, Cristian O. Salas   +12 more
doaj   +2 more sources

Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-κB signaling and depleting Bcr-Abl

Molecular Cancer, 2010
Background Chronic myelogenous leukemia (CML) is characterized by the chimeric tyrosine kinase Bcr-Abl. Bcr-Abl-T315I is the notorious point mutation that causes resistance to imatinib and the second generation tyrosine kinase inhibitors, leading to poor
Jingxuan Pan
exaly   +3 more sources

Targeted disruption of the BCR-ABL fusion gene by Cas9/dual-sgRNA inhibits proliferation and induces apoptosis in chronic myeloid leukemia cells [PDF]

Acta Biochimica et Biophysica Sinica
The BCR-ABL fusion gene, formed by the fusion of the breakpoint cluster region protein (BCR) and the Abl Oncogene 1, Receptor Tyrosine Kinase (ABL) genes, encodes the BCR-ABL oncoprotein, which plays a crucial role in leukemogenesis.
Zeng Jianling, Liang Xinquan, Duan Lili, Tan Fenghua, Chen Liujie, Qu Jiayao, Li Jia, Li Kai, Luo Dixian, Hu Zheng   +9 more
doaj   +2 more sources

A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway

Molecular Therapy - Oncolytics, 2020
Chronic myeloid leukemia (CML) is caused by the Philadelphia (Ph+) chromosome carrying the BCR-ABL oncogene, a constitutively active tyrosine kinase. The discovery of imatinib represents a major success story in the treatment against CML.
Luca Vincenzo Ballestra, Yu Ke, Xin Xu
exaly   +2 more sources

Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features

Frontiers in Oncology, 2020
BackgroundRecently, various blood cell lineages expressing the BCR-ABL fusion gene in Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have been reported. However, the biological and clinical significance of these BCR-ABL lineages
Satoshi Nishiwaki, Masafumi Ito, Yusuke Okuno   +2 more
exaly   +3 more sources

Sphagneticola Trilobata (L.) Pruski (Asteraceae) Methanol Extract Induces Apoptosis in Leukemia Cells through Suppression of BCR/ABL

Plants, 2021
We will study the effects of the methanol extract of Sphagneticola trilobata (L.) Pruski (Asteraceae) (MeST) on the growth of leukemia cells that may contain the BCR/ABL gene. This study also clarifies the mechanism of this effect on these cells.
Hoang Thanh Chi, Nguyen Thi Lien Thuong, Bui Thi Kim Ly   +2 more
doaj   +1 more source

Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis

Cell Death and Disease, 2021
Chronic myelogenous leukemia (CML) is a clonal malignancy of hematopoietic stem cells featured with the fusion protein kinase BCR-ABL. To elicit the mechanism underlying BCR-ABL stability, we perform a screen against a panel of deubiquitinating enzymes ...
Shuoyi Jiang, Xiaoge Wang, Yuanming He, Hongbiao Huang, Biyin Cao, Zubin Zhang, Jinbao Liu, Qi Wang, Zhenqian Huang, Xinliang Mao   +9 more
doaj   +1 more source